Propel testing excellence with Mayo Clinic quality
Mayo Clinic Laboratories is a one-stop laboratory solution, offering commercial laboratories a vast testing menu, unparalleled customer service, and optimized processes. We work collaboratively with partners to assess their needs, providing the testing they need to expand into new areas and meet their business goals.
As the reference lab for Mayo Clinic, we’ve developed robust logistics and testing protocols applied uniformly for all specimens received, no matter their geographic origin. Whether you send us one test order or thousands, each sample receives the same treatment and level of care, ensuring superior results that help our partners better serve their clients.
“Our clients want personal experiences. They want someone to answer the phone. They want someone to provide answers when they're looking for results of a sample sent a couple days ago. and we deliver those answers.”
Angie Reese-Davis, director of operations, logistics, and specimen services, Mayo Clinic Laboratories
Our difference
News and updates
The latest
In this episode of the “Leveraging the Laboratory” podcast, Jane Hermansen, outreach manager at Mayo Clinic Laboratories, welcomes Chelsea Conn, Mayo Clinic Laboratories’ director of regulatory affairs. Together, they break down the latest regulatory changes and share actionable strategies to help outreach programs stay informed and prepared.
At just 24-years-old Anya Magnuson has survived not just one but two close encounters with death. Focused, determined, and intent on experiencing life to its fullest, Anya never gave up. Nor did the multidisciplinary Mayo Clinic care team who worked tirelessly to heal her.
Topic highlights include: Mayo: urgent need for O- blood types, Optum, Sanofi team to make low-cost insulin available to uninsured, How the COVID-19 pandemic changed Americans’ health for the worse.
In this episode of “Lab Medicine Rounds,” Justin Kreuter, M.D., sits down with Bobbi Pritt, M.D., professor of Laboratory Medicine and Pathology and division chair for the Department of Clinical Microbiology at Mayo Clinic, to discuss why this year’s tick season is more severe than others.
In July 2022, Mayo Clinic Laboratories announced fifteen new tests along with numerous reference value changes, obsolete tests, and algorithm changes.
John Osborn, operations administrator in the Department of Laboratory Medicine and Pathology at Mayo Clinic, joins the "Answers From the Lab" podcast for a discussion with host Bobbi Pritt, M.D. about monkeypox testing. In this episode, John and Dr. Pritt discuss how Mayo Clinic swiftly operationalized monkeypox testing and the challenges involved with supporting the new assay, including staffing.
Todd Walker is a laboratory supervisor for Mayo Clinic Laboratories, Specimen Operations, where he helps lead the department that serves as the gateway between collecting and delivering specimens and getting them processed. Todd credits his diverse, agile team and the impressive global logistics infrastructure that allows them to support the processing of 40,000 specimens in a day.
Rajiv Pruthi, M.B.B.S., explains how Mayo Clinic Laboratories’ serotonin release assay achieves high sensitivity and specificity while avoiding the use of radioactive materials. Serotonin release testing is an important tool in the diagnosis of heparin induced thrombocytopenia, or HIT, which can have devastating consequences for patients.
This week's research roundup features: Gastrointestinal stromal tumors mimicking gynecologic disease: clinicopathological analysis of 20 cases.
This page includes updates posted to mayocliniclabs.com during the month of July.
In this month's "Hot Topic," Rajiv Pruthi, M.B.B.S., discusses heparin induced thrombocytopenia (HIT), approach diagnosis, and the role of the functional serotonin release assay (SRA).
Topic highlights include: Mayo Clinic in Rochester again ranked country's top hospital: U.S. news and world report, WHO declares monkeypox a global health emergency as infections soar, Depression is likely not caused by a chemical imbalance in the brain, study says.
William Morice II, M.D., Ph.D., president of Mayo Clinic Laboratories, shares his concerns about the VALID Act, which if passed would give the FDA oversight of laboratory-developed tests. VALID could hamper labs’ test development activity, increase costs for labs, and disproportionately affect smaller labs or those with fewer resources. It could also lead to more test development partnerships and lab collaboration.